MACK

Merrimack Pharmaceuticals, Inc. Press Releases

$9.03
*  
0.07
0.77%
Get MACK Alerts
*Delayed - data as of Nov. 21, 2014  -  Find a broker to begin trading MACK now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Viewing
Filtered By
Ordered By
Merrimack Pharmaceuticals Presents on Multiple Programs at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
11/21/2014 8:00:00 AM - GlobeNewswire


PharmaEngine Announces the Receipt of US FDA Fast Track Designation for MM-398 in Post-Gemcitabine Metastatic Pancreatic Cancer by Merrimack
11/20/2014 1:24:00 AM - Business Wire


Merrimack Pharmaceuticals Receives FDA Fast Track Designation for MM-398 in Post-Gemcitabine Metastatic Pancreatic Cancer
11/19/2014 8:00:00 AM - GlobeNewswire


Photo Release -- Merrimack Pharmaceuticals Announces the Addition of Vivian S. Lee, Dean of University of Utah School of Medicine, to Its Board of Directors
11/17/2014 8:30:00 AM - GlobeNewswire


Merrimack Pharmaceuticals to Present Advances on Targeted Cancer Molecules at the 2014 AACR-NCI-EORTC International Conference
11/13/2014 8:00:00 AM - GlobeNewswire


Merrimack Pharmaceuticals Reports Third Quarter 2014 Financial Results
11/10/2014 4:01:00 PM - GlobeNewswire


Merrimack Pharmaceuticals Announces Initiation of Phase 1 Clinical Study of MM-398 for Brain Cancer
11/6/2014 8:30:00 AM - GlobeNewswire


FDA Grants Orphan Drug Designation to Merrimack Pharmaceuticals' MM-141 for the Treatment of Pancreatic Cancer
11/5/2014 9:00:00 AM - GlobeNewswire


Merrimack Pharmaceuticals Announces Timing of Third Quarter 2014 Investor Conference Call
11/3/2014 8:00:00 AM - GlobeNewswire


Merrimack Pharmaceuticals Presents Additional Phase 2 Biomarker Data Further Strengthening the Finding That MM-121 Increases Progression Free Survival in Patients With Biomarker Positive Metastatic Breast Cancer
9/30/2014 8:00:00 AM - GlobeNewswire


PharmaEngine and Merrimack Amend MM-398 License Agreement
9/26/2014 4:56:00 AM - Business Wire


Baxter and Merrimack Pharmaceuticals Enter into Exclusive Ex-U.S. Licensing Agreement to Develop and Commercialize Novel Cancer Compound MM-398
9/24/2014 7:00:00 AM - Business Wire


Merrimack Pharmaceuticals to Present Clinical and Biomarker Data on Novel Antibody Therapeutics at the ESMO 2014 Congress
9/19/2014 8:00:00 AM - GlobeNewswire